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Abstract - Purpose. To investigate literature 
about pharmacological, surgical, and diagnostic 
innovations for Meniere’s Disease (MD) 
Summary. Meniere’s disease is an inner ear 
disorder characterized by the presence of 
endolymphatic hydrops in the inner ear and 
symptomatology of recurrent and debilitating vertigo 
attacks, tinnitus, aural fullness, and fluctuating 
sensorineural hearing loss. Although many 
therapeutic options for MD have been proposed 
during years, no consensus has been reached by the 
scientific community. In the last decade, many 
therapeutic options have been proposed, as 
intratympanic steroid, intratympanic gentamicin, and 
intravenous glycerol. Recently, the role of the 
antisecretory factor in the diet of MD patients have 
been investigated. Surgery is recommended for 
intractable MD; some authors proposed new 
approaches including transcanal endoscopic 
infracochlear vestibular neurectomy, new 
marsupiliazation technique in sac surgery, and 
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I.  INTRODUCTION 
 
 Meniere disease (MD) is an inner ear disorder 
characterized by the presence of endolymphatic hydrops 
(EH) in the inner ear and symptomatology of recurrent 
and debilitating vertigo attacks, tinnitus, aural fullness, 
and fluctuating sensorineural hearing loss (SNHL)
1,2,3
. 
Although hearing loss is mainly sensorineural, low-
frequency air-bone gap (ABG) can also be found in the 
absence of middle ear pathology
4
, mimicking other 
conditions such as cerebral vascular anomalies including 
dural arteriovenous fistula
5
. MD symptoms can severely 
affect the quality of life
6,7
.  
Although many therapeutic options for MD have been 
proposed, no consensus has been reached by the scientific 
community
8-11
. First-line treatment includes dietary 
restrictions for salt, caffeine, and alcohol associated to 
drugs both for acute attacks (dimenhydrinate, 
benzodiazepines)
12




When first-line treatment does not offer satisfactory 
symptom control, intratympanic (IT) administration of 
gentamicin or corticosteroids can be performed
14
; 
however, many studies showed that IT gentamicin may 
expose the patients to a risk of hearing loss, depending on 
dosage and intervals between administrations
15
. 
Labyrinthectomy or other surgical procedures can be 
suggested for intractable MD
16
. 
Despite the recent COVID-19 pandemic
17-20
, scientific 
research for MD is a growing area in continuous 
development. This brief review aims to assess the clinical 
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The main goal of the pharmacological treatment of MD is 
to reduce the duration and frequency of vertigo attacks, 
and to prevent hearing loss, which is usually progressive. 
There’s lack of high-level evidences for efficacy of MD 
treatment; for this reason, different drugs and different 
methods of administration have being tested. 
IT steroids (dexamethasone, methylprednisolone) 
treatments have been widely used for MD, especially 
when first-line treatment does not offer a satisfactory 
symptoms control; however,  there is still lack of evidence 





 evaluated the effects of IT dexamethasone 
in 30 patients with refractory MD comparing the pre- and 
post-treatment hearing outcome and dizziness score. They 
found that 23% of patients were free of vertigo at the end 
of 24 months after IT steroids, but there was no significant 
improvement in hearing. These results are in accordance 
with those from Weckel et al
23
 who retrospectively 
evaluated 25 patients treated with IT dexamethasone; they 
reported a satisfactory control of vertigo in 92% of the 
patients, and this protocol achieved control of vertigo in 
70% of patients at 2 years. Harcourt et al
24
 suggested IT 
methylprednisolone as an effective treatment for the long-
term control of vertigo attacks, without he known inner-
ear toxicity associated with gentamicin. 
Gentamicin, administered at different doses and timing
25
, 
has been proven as an effective treatment for vertigo 
control in MD with a potential risk of herring loss; 
however, discussion about the dosage and the method 
used is open
26
. Scarpa et al
27
 proposed a low-dose IT 
gentamicin protocol; they treated 48 patients with 0.5 ml 
of 10 mg of gentamicin with an interval of 2 weeks 
between injections. They reported a satisfactory control of 
vertigo attacks after IT gentamicin, and the effect of this 
protocol on vestibular system was proved by the reduction 
in vestibulo-ocular reflex (VOR) gain in the affected side. 
A meta-analysis from Jian et al
28
 demonstrated that IT 
gentamicin is superior to IT steroids in reducing the 
number of vertigo attacks, but both drugs didn’t show 
hearing improvement. 
Moreover, Ozturk and Ata proposed an IT mixture of 
gentamicin and dexamethasone injection for the treatment 
of intractable MD, even more effective that IT 
dexamethasone for vertigo control
29
. 
Diuretics have also been recommended to control vertigo 
attacks in MD, due to their effects in reducing the 
endolymphatic pressure and volume. As for steroids and 
gentamicin, there are no high-quality data demonstrating 
the efficacy of oral diuretic therapy
30
; in addition, a meta-
analysis from Rosenbaum and Winter
31
 concluded that it 
is not clear if diuretic lead to a symptomatic improvement 
of vertigo. 
A prospective study from Scarpa et al
32
 evaluated the 
effectiveness on vertigo control of intravenous (IV) 
glycerol (an osmotic diuretic), 10% glycerol with 0.9% 
sodium chloride, 0.5 g/kg once a day for 2 consecutive 
days every fifteen days for six months; the authors 
reported an improvement of vertigo attacks and a 
significant reduction of discomfort generated by tinnitus, 
raising quality of life. 
Recently, some authors suggested a possible action of 
anti-secretory factor (AF), a protein produced by pituitary 
gland that plays a role in the innate defense against the 
inflammatory and secretory components of diarrheal 
disease
33
. It has been hypothesized that AF can act as a 
modulator of water and ions and interact with the 
aquaporins. Viola et al
34
 observed a significant 
improvement in daily activities in patients treated with 
specially processed cereals (SPC) compared to those 
treated with IV glycerol and dexamethasone. The study 
reported a significant reduction of vertigo spells and a 




According to international guidelines, surgical therapy for 
MD is recommended only for refractory disease, and 
therefore represents the third (or even the fifth) line of 
management. Currently, the most popular surgical 
procedures to control vertigo attacks in MD are also the 
most aggressive and those that have the most negative 
impact on auditory function. Besides, there is a lack of 
evidence suggesting that surgical therapy for MD may 
provide a significant control of symptoms
35
. 
The table below shows the main surgical procedures for 
MD taking into account of hearing preservation, vestibular 
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Endolymphatic sac surgery (ESS) can be considered in 
patients that are refractory to medical management as a 
nondestructive option, as the risk to damage hearing is 
low
36
. Xu et al
37
 suggested that ESS with posterior 
tympanotomy and local steroid treatment could improve 
hearing and ensure a satisfactory vertigo control in 
patients with intractable MD. In Gibson et al opinion
38
, 
ESS can provide a vertigo control at least as well as IT 












triple semicircular canal plugging
43
 have been proposed as 
an effective surgical option for the treatment of MD. 
New techniques have been recently described. Daneshi et 
al
44
 evaluated the results of a new marsupialization 
technique in endolymphatic sac decompression surgery, in 
which the outer layer of the sac was turned around and 
placed under the anterior bony border. They concluded 
that this technique can control progressive hearing loss 
and improve tinnitus, vertigo, and ear fullness among 
patients with intractable unilateral MD. 
Moreover, Trakimas et al
45
 proposed a transcanal 
endoscopic infracochlear vestibular neurectomy on 
cadaver as a minimally invasive approach to distal 
vestibular neurectomy. 
More recently, some authors suggested that tenotomy of 
the stapedius and tensor tympani muscles (TSTM) may be 
a safe surgical procedure with significant vertigo control, 







In the diagnosis and the evaluation of therapy efficacy, the 
audio-vestibular test battery has a primary role, and the 
diagnostic findings are constantly evolving. 
Di Stadio et al proposed head-shaking nystagmus (HSNy) 
as a useful test in the early stages of MD to predict a new 
vertigo attack, with a sensitivity of the ipsilesional HSNy 
of 100% at T0 and 85.7% at T1
47
. 
Lee SU et al
48
 evaluated the VOR performance during the 
attacks of MD using video head-impulse tests (video-
HITs) according to each ictal phase; the authros suggested 
that during the vertigo attack, HITs are normal during 
irritative and recovery phases, but abnormal in 53% of the 
patients during the paretic phase, reflecting characteristic 
ictal vestibular discharges. Besides, a common finding in 
MD is a normal horizontal HIT with an asymmetric 




Patients with suspected MD can be examined using 
magnetic resonance imaging (MRI) to evaluate a possible 
inner ear disease. The MRI findings in patients with MD 
are conflicting, due to the MRI sequences used and the 
inclusion criteria of the patients; also, the early stage of 
MD and the early symptoms appear too subtle for 
identification using MRI, making the reproducibility of 






III.  CONCLUSION 
 
 Despite accumulating evidence for the treatment 
of MD, there is currently no international consensus on a 
standardized therapeutic protocol for this condition. 
Intravenous administration of glycerol, low-dose 
intratympanic gentamicin, and antisecretory factor are 
promising innovations. 
The role of surgery in the treatment of MD is still debated; 
recent techniques as tenotomy of the stapedius and tensor 
tympani muscles seems to offer interesting insights, but 
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